Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)
Completed · Phase 1 · NCT03703167
Conditions: Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL)
At a glance
- Research payments reported, 2025
- $512,820
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 25
About the trial
- Sponsor
- Memorial Sloan Kettering Cancer Center (with Pharmacyclics LLC.)
- Tested
- Ibrutinib (drug), Lenalidomide (drug), Rituximab (drug)
- Dates
- Started 2019-01-22; completion 2026-01-26
- Results posted
- Not yet
The investigator's want to find out if treatment with ibrutinib, rituximab, and lenalidomide are safe and better than the usual approach in patients with recurrent or refractory central nervous system lymphoma.
From ClinicalTrials.gov, last updated 2026-01-29. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $512,820 in research payments for this study in 2025 (2 payments).
Products named: Imbruvica
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Memorial Sloan Kettering Cancer Center $512,820
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.